NeuroPace
NeuroPace markets the FDA-approved RNS System, a closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The platform serves Level 4 epilepsy centers in the US and is expanding into generalized epilepsy indications and AI-driven clinical decision support tools.
- Company typePublic
- Founded1997
- HeadquartersMountain View, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuroPace does
NeuroPace, Inc. is a Mountain View, California-based medical device company founded in 1997 and publicly traded on NASDAQ under the ticker NPCE. The company developed the RNS (Responsive Neurostimulation) System, the only FDA-approved closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The system comprises an implantable neurostimulator connected to intracranial leads that detect patient-specific EEG patterns and deliver targeted electrical stimulation to abort seizures. Clinical evidence from a three-year Post-Approval Study published in Neurology demonstrated 82% median seizure reduction across 324 patients at 32 U.S. centers, and 8,000+ patients are monitored through the FDA-cleared platform.
The RNS System is complemented by a cloud-based software platform that includes the nSight clinician portal for remote patient monitoring, the tablet-based Patient Data Management System (PDMS) for in-clinic review and device programming, and the FDA-approved ECoG Assistant AI tool for intracranial EEG analysis. NeuroPace is pursuing indication expansion into idiopathic generalized epilepsy via the NAUTILUS pivotal trial, with a PMA supplement filed in December 2025 and mid-2026 FDA approval targeted. The company is also evaluating the RNS System for Lennox-Gastaut Syndrome under an NIH-funded feasibility study.
Revenue is generated primarily from RNS System device sales recognized upon implantation and replacement, distributed through approximately 200+ Level 4 comprehensive epilepsy centers in the United States via direct field sales. FY2025 revenue reached approximately $100 million, representing 25% year-over-year growth, with Q1 2026 revenue of $22.1 million. Reimbursement improved materially effective January 1, 2026, with hospital replacement reimbursement rising 47% and physician fees increasing 43-45%. NeuroPace is exiting its non-core DIXI Medical distribution business by June 30, 2026 to focus on its pure-play RNS strategy.
NeuroPace firmographics
Firmographics- Name
- NeuroPace
- Legal name
- NeuroPace, Inc.
- Website
- https://neuropace.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NeuroPace markets the FDA-approved RNS System, a closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The platform serves Level 4 epilepsy centers in the US and is expanding into generalized epilepsy indications and AI-driven clinical decision support tools.
- Ownership category
- akta.pro rank
NeuroPace industry classification
Industry- Product category
- Implantable Neurostimulators
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where NeuroPace is headquartered
LocationHeadquarters
- HQ city
- Mountain View
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeuroPace business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- RNS System Device Sales: Primary revenue driver from initial implantation procedures and subsequent device replacements. Revenue recognized upon device implantation and replacement. Q1 2026 RNS System revenue of $21.7 million representing 18.5-19.5% year-over-year growth.
- Medicare/Commercial Reimbursement: Hospital and physician reimbursement for RNS procedures. Medicare reimbursement updates effective January 1, 2026 increased physician payments by approximately 43% for initial implant and 45% for replacement procedures. Hospital replacement reimbursement rose 47% to $31,526 from $21,444.
- Discontinued DIXI Distribution: Non-core distribution business being exited by June 30, 2026. Revenue contribution from DIXI Medical excluded in non-GAAP reporting (e.g., Q1 2026 non-GAAP revenue of $22.0M excludes DIXI).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Per procedure | Hospital outpatient reimbursement for RNS System replacement procedures |
| Transaction based/ take rate | Per procedure | Physician professional fees for RNS procedures |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
NeuroPace product offering
Product offeringCore offering
NeuroPace develops and markets the RNS (Responsive Neurostimulation) System, the first and only FDA-approved closed-loop brain-responsive neuromodulation device, which monitors intracranial electrocorticography (ECoG) signals and delivers targeted electrical stimulation to abort seizures in adults with drug-resistant focal epilepsy. The core revenue-generating offering is the implantable neurostimulator plus NeuroPace-supplied leads and supporting clinician software, sold to Level 4 epilepsy centers and implanted by neurosurgeons. Supporting software products include the nSight cloud platform, the ECoG Assistant AI analysis tool, and the Patient Data Management System (PDMS).
Product overview
NeuroPace offers a unified epilepsy treatment platform centered on the RNS System, a brain-responsive neuromodulation device that delivers personalized, closed-loop stimulation therapy for drug-resistant focal epilepsy. The platform integrates multiple components: the RNS neurostimulator (including RNS-320 and RNS-300M models) and leads implanted in the brain; the nSight cloud-based clinician platform for remote patient monitoring and data access; the Patient Data Management System (PDMS) for in-clinic data review and device programming; and the FDA-approved ECoG Assistant AI tool for automated intracranial EEG analysis. The company is strategically shifting toward software-driven growth with its AI-powered tools, migrating clinician platforms to cloud infrastructure, while focusing on its core RNS franchise for epilepsy treatment.
Differentiator
Problem solved
Functional benefit
Brands
- RNS System: Brain-responsive neuromodulation device for treating drug-resistant epilepsy
- ECoG Assistant
- nSight Platform
- PDMS
Products and services
- RNS System (Responsive Neurostimulation System)
Quantifiable outcome
- 82% median seizure reduction at 3 years in drug-resistant focal epilepsy patients (Post-Approval Study, 324 patients, 32 centers)
- +5 more outcomes
Companies that use NeuroPace
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles1 record
NeuroPace technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
NeuroPace partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- DIXI MedicalminorFormer distribution partnership for DIXI Medical products in the U.S. NeuroPace announced early termination of this non-core distribution business to focus on its pure-play RNS strategy. Exit expected by June 30, 2026.
- FDA (NEST - National Evaluation System for Health Technology)coreCollaboration with FDA's NEST program, funded by an FDA grant to MDIC, facilitating real-world evidence in device submissions including pediatric device approvals. NeuroPace working with NEST to navigate regulatory processes using real-world data.
Scale indicators16 records
Recent moves8 records
Expansion highlights5 records
NeuroPace competitors and assessment
Company assessmentDirect peers
- LivaNova: LivaNova markets VNS Therapy (vagus nerve stimulation), the other primary FDA-approved neuromodulation therapy for drug-resistant epilepsy. Most directly comparable competitor in epilepsy neuromodulation, though using open-loop stimulation versus NeuroPace's closed-loop approach.
Broad incumbents
- Medtronic: Medtronic offers the Percept PC DBS system with BrainSense sensing for epilepsy and other indications. A broad incumbent in neuromodulation with deep R&D resources and global distribution, posing long-term competitive risk in closed-loop technology.
- Boston Scientific: Boston Scientific acquired VNS Therapy from Cyberonics and markets a broad neuromodulation portfolio including spinal cord and deep brain stimulators. Large incumbent with diversified indications and global commercial reach.
- Abbott: Abbott's Neuromodulation division markets Proclaim DRG and Infinity DBS systems across multiple indications. A diversified incumbent with scale advantages in R&D, clinical evidence, and global distribution.
Emerging players
- Inspire Medical Systems: Inspire Medical Systems markets hypoglossal nerve stimulation for obstructive sleep apnea. Comparable as a specialized implantable neurostimulator company that scaled from a narrow indication, illustrating the growth template NeuroPace could follow.
- Axonics: Axonics markets sacral neuromodulation systems for incontinence and overactive bladder. Comparable as a smaller, focused implantable neurostimulator company pursuing indication expansion in adjacent therapeutic areas.
- Nevro: Nevro markets HF10 high-frequency spinal cord stimulation for chronic pain. Comparable as a specialized neuromodulation company with proprietary stimulation technology competing against incumbents in a defined clinical market.
- electroCore: electroCore markets gammaCore non-invasive vagus nerve stimulation for migraine and cluster headache. Comparable as a neuromodulation company pursuing adjacent neurological indications with differentiated delivery modality.
- Saluda Medical: Saluda Medical is developing Evoke closed-loop spinal cord stimulation for chronic pain. Comparable as a closed-loop neuromodulation technology developer pursuing a different indication with similar responsive-stimulation architectural approach.
Others
- Cirtec Medical: Cirtec Medical is a contract manufacturer specializing in neuromodulation and active implantable devices. Adjacent ecosystem participant providing manufacturing services to NeuroPace and its peer neuromodulation OEMs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NeuroPace social profiles
Digital presenceNeuroPace financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroPace leadership team
Management profileNumber of profiles
Profiles13 records
NeuroPace funding detail
Funding detailFunding overview
Funding rounds11 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroPace M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroPace
What does NeuroPace do?
NeuroPace develops and markets the RNS (Responsive Neurostimulation) System, the first and only FDA-approved closed-loop brain-responsive neuromodulation device, which monitors intracranial electrocorticography (ECoG) signals and delivers targeted electrical stimulation to abort seizures in adults with drug-resistant focal epilepsy. The core revenue-generating offering is the implantable neurostimulator plus NeuroPace-supplied leads and supporting clinician software, sold to Level 4 epilepsy centers and implanted by neurosurgeons. Supporting software products include the nSight cloud platform, the ECoG Assistant AI analysis tool, and the Patient Data Management System (PDMS).
Is NeuroPace a public or private company?
NeuroPace is a public company. It is classified as public and is currently operating.
When was NeuroPace founded?
NeuroPace was founded in 1997. It employs 101 to 250 people.
Where is NeuroPace based?
NeuroPace is headquartered in Mountain View, United States, in the North America region.
How does NeuroPace make money?
Three revenue lines are on record. RNS System Device Sales are the primary driver. The others are medicare/Commercial Reimbursement and discontinued DIXI Distribution.
Who are NeuroPace's main competitors?
LivaNova is listed as a direct peer. Broad incumbents are Medtronic, Boston Scientific and Abbott. Emerging players are Inspire Medical Systems, Axonics, Nevro, electroCore and Saluda Medical. Cirtec Medical is listed as an others.
Does NeuroPace have an API?
No public API is recorded for NeuroPace.
What industry is NeuroPace in?
NeuroPace's product category is Implantable Neurostimulators. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.